US 2025/0019372 A1Published application

Crystalline forms of a ripk1 inhibitor

AssigneeRigel Pharmaceuticals, Inc.

InventorsShaoming DUAN, Simon SHAW, Xin WANG

Life of this patent

Estimating the term…

Abstract

The present invention provides a crystalline compound of the formula: wherein the crystalline compound is useful for treating autoimmune and inflammatory diseases, such as atopic dermatitis, rheumatoid arthritis, and psoriasis.

Claims22

Dependent claims

A crystalline form of a compound of the formula:

Dependencies are inferred from the claim text.

Facts

Application: 18/711,541Filed 7 Dec 2022
Priority: 16 Dec 2021
Published: 16 Jan 2025
Term ends: Not estimatedThe source records don’t support an estimate.

Classification7 codes

C07D 413/12
Containing two hetero rings: linked by a chain containing hetero atoms as chain links
A61K 31/553
Having seven-membered rings, e.g. azelastine, pentylenetetrazole: having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine,…
A61P 29/00
Non-central analgesic, antipyretic or antiinflammatory agents
A61P 37/02
Drugs for immunological or allergic disorders: immunomodulators

Family

Application63/290,066Us provisional application · filed 16 Dec 2021
US 2025/0019372 A1This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

Building an agent or pulling many patents? Use the API or MCP server instead of scraping pages. Get an API key

patentgrep

Loading patent…

patentgrepSearch patents

Back to results